![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
June 30, 2023
This phase 3 study aims to determine the optimal sequencing of surgery, chemotherapy, and chemoradiotherapy for patients with cancer of the penis
February 10, 2023
This phase 3 study is comparing the efficacy of intravesical chemotherapy after surgery to the usual approach of intravesical immunotherapy after surgery
October 13, 2022
Research results in breast and kidney cancer; recognition of key colleagues; and a sneak peek of the Fall 2022 Group Meeting
October 13, 2022
The phase III PROSPER RCC clinical trial demonstrated that priming the immune system with nivolumab before surgery, then continuing nivolumab, did not improve recurrence-free survival in patients with high-risk renal cell carcinoma
October 13, 2022
Summaries of recently published ECOG-ACRIN research results
August 16, 2022
This phase 3 study is using PET/CT imaging to guide treatment for patients with post-prostatectomy biochemical recurrence
August 16, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 15, 2022
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
November 16, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
August 17, 2021
This phase II study is testing the effects and safety of green tea catechins (GTC) as a chemopreventive agent
July 7, 2021
This phase II/III study is comparing the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery
May 28, 2021
Researchers with the ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present a wide range of research findings at the 2021 ASCO Annual Meeting